Eton and Aquestive Announce U.S. Licensing Agreement for LIBERVANT
Eton Pharmaceuticals and Aquestive Therapeutics announced an exclusive U.S. licensing agreement for LIBERVANT (diazepam) buccal film.
Story updates
10:52:09 AM UTC
SquawkNews
Eton licensed exclusive U.S. commercialization rights to LIBERVANT buccal film from Aquestive, with commercial availability targeted for April 2027, subject to final FDA approval and VALTOCO exclusivity expiry in Jan. 2027.Material DetailsContext by AI AnalystThis is an early-stage strategic expans…